Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tigulixostat DDI with Theophylline
NCT06189404Phase 1Completed
- Sponsor
- LG Chem
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tigulixostat in gout and hyperuricemia, sponsored by LG Chem. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t up to 72 hours, Area Under the Concentration-Time Curve From Time Zero to Infinity up to 72 hours and 1 more. Started Oct 2023; status: completed.
02
Drugs
tigulixostat
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06189404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189404.